Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study

Fig. 2

Cumulative incidence of leptomeningeal metastasis in patients after propensity score matching. a Osimertinib group vs Control group; b First-line osimertinib vs Second-line osimertinib; c Exon 19 deletion vs Other EGFR mutations; d Polymetastasis vs Oligometastasis. LM leptomeningeal metastasis, EGFR epidermal growth factor receptor

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us